Moderna CEO Stéphane Bancel at a meeting with President Donald Trump, members of the White House coronavirus task force, and pharmaceutical executives on March 2. Andrew Harnik/AP Images Moderna on Monday will file for emergency-use authorization of its experimental coronavirus vaccine, the company said. The biotech company said the vaccine was 94.1% effective against COVID-19 in an analysis of a late-stage trial. If the Food and Drug Administration authorizes the vaccine, the US intends to start vaccinating vulnerable people before the end of 2020. For more stories like this, sign up here for Business Insider's daily healthcare newsletter. Moderna is set to ask US regulators to allow the emergency use of its coronavirus vaccine, starting a process that could allow the shot to be given more widely within weeks.The biotech company plans to file for emergency-use authorization with the US Food and Drug Administration on Monday, Moderna said in a statement, about a week after Pfizer and BioNTech asked the FDA to authorize their vaccine.